Foresite Capital Management IV, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 13, 2024), Foresite Capital Management IV, LLC reported 4 stock positions worth $148.8 million. Its top holding was Pharvaris (PHVS) at 54.2% of the portfolio, followed by Kura Oncology (KURA, 25.6%) and Syndax Pharmaceuticals (SNDX, 12.1%). Compared with Q1 2024, it sold out of 1 and added to 1. The biggest buy was Pharvaris (PHVS, shares +6%) and the biggest sale an exit from Kinnate Biopharma (KNTE).
- Most Recent 13F
- Q2 2026
- Location
- WEST HOLLYWOOD, CA
- CIK
- 0001704132
- Portfolio Value
- $148.8M (Q2 2024)
- SEC Filing
- 0001104659-24-088863 ↗ filed Aug 13, 2024
Holdings Value
Holdings 4 stocks · $148.8M
Portfolio Sells Q1 2024 → Q2 2024
| KNTE Kinnate Biopharma Inc. | Sold out | 0.00% | −13.00 |
Portfolio Buys Q1 2024 → Q2 2024
| PHVS Pharvaris NV | Add +6.3% | 54.23% | +7.07 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 6 | $290.2M | PHVS, CYTK, EIKN, RLAY, XENE |
| Q1 2026 | 8 | $237.1M | PHVS, CYTK, EIKN, LYEL, RLAY |
| Q4 2025 | 7 | $229.7M | PHVS, CYTK, LYEL, MAZE, RLAY |
| Q3 2025 | 6 | $182.6M | PHVS, CYTK, MAZE, LYEL, XENE |
| Q2 2025 | 6 | $123.8M | PHVS, MAZE, LYEL, XENE, KURA |
| Q1 2025 | 5 | $111.1M | PHVS, MAZE, LYEL, KURA, RLAY |
| Q4 2024 | 4 | $108.8M | PHVS, KURA, LYEL, RLAY |
| Q3 2024 | 5 | $153.0M | PHVS, KURA, SNDX, LYEL, RLAY |
| Q2 2024 | 4 | $148.8M | PHVS, KURA, SNDX, LYEL |
| Q1 2024 | 5 | $197.9M | PHVS, KURA, KNTE, SNDX, LYEL |